혈전 관리 디바이스 시장 규모, 점유율, 동향 및 예측 : 제품 유형, 최종사용자, 지역별(2026-2034년)

The global clot management devices market size was valued at USD 2.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 3.0 Billion by 2034, exhibiting a CAGR of 4.40% during 2026-2034. North America currently dominates the market, holding a significant market share of over 55.3% in 2025. The rising prevalence of cardiovascular diseases, an aging population, increasing demand for minimally invasive procedures, and technological advancements are some of the key factors fueling the clot management devices market share.

The market for clot management devices is driven by the rising prevalence of deep vein thrombosis, cardiovascular diseases, stroke, and pulmonary embolism, which increase the demand for effective clot removal solutions. A rapidly increasing geriatric population, more susceptible to thrombotic disease, fuels the market further. Advances in technology for minimally invasive procedures improve patient outcomes with shorter hospital stays and recovery periods. Greater awareness of early detection and treatment of clots and favorable reimbursement practices drive adoption. Additionally, rising healthcare expenditures, government support for advanced medical technologies, and the expansion of specialized treatment centers contribute to market growth. The presence of key medical device manufacturers and ongoing research into innovative thrombectomy techniques also drive the industry's competitive landscape.

The market for clot management devices in the United States is driven by the high prevalence of deep vein thrombosis, cardiovascular diseases, and pulmonary embolism. The country's advanced healthcare infrastructure, increasing adoption of minimally invasive procedures, and strong presence of leading medical device manufacturers contribute to market growth. Favorable reimbursement policies and high healthcare spending enhance access to advanced treatments. Additionally, rising awareness about early clot detection, a growing geriatric population, and technological advancements in thrombectomy devices fuel demand. For instance, in January 2025, Argon Medical Devices reported the initial patient enrollment in the CLEAN-PE study, which seeks to assess the safety and effectiveness of the Cleaner Pro thrombectomy system for extracting blood clots from the lungs of patients diagnosed with pulmonary embolism (PE). It is anticipated that more than 100 patients are enrolled in CLEAN-PE at different hospitals throughout the United States. Government support, ongoing research and development, and an increasing number of outpatient procedures further propel the market's expansion in the U.S.

Clot Management Devices Market Trends:

Rising Prevalence of Cardiovascular Diseases and Thrombotic Disorders

The increasing incidence of cardiovascular diseases, stroke, deep vein thrombosis, and pulmonary embolism is a major driver of the clot management devices market. Sedentary lifestyles, obesity, smoking, and hypertension contribute to higher cases of blood clots, necessitating effective treatment solutions. An aging global population further escalates the risk of thrombotic disorders, increasing demand for advanced clot removal technologies. According to recent industry reports, in 2024, 12% of the global population was aged 60 years and above, equating to 1.2 Billion individuals. This number is expected to rise to 2.1 Billion by 2050, making up 26% of the total population in the world. The growing awareness about early diagnosis and intervention has led to higher adoption of clot management devices in hospitals and specialized clinics. This rising disease burden continues to push the research, development, and commercialization of innovative clot removal technologies.

Technological Advancements in Clot Management Devices

Ongoing innovations in clot management devices, such as percutaneous thrombectomy systems, catheter-directed thrombolysis, and mechanical thrombectomy devices, are revolutionizing patient care. These advancements allow for minimally invasive procedures, reducing recovery time and hospital stays while improving patient outcomes. Modern thrombectomy devices offer enhanced precision and efficiency, making procedures safer and more effective. Artificial intelligence, robotics, and real-time imaging further contribute to improved clot removal techniques. As healthcare providers seek better, faster, and safer treatment options, continuous product development and regulatory approvals drive the adoption of advanced clot management technologies. For instance, in September 2024, The CLEANER VacTM Thrombectomy System, which is intended to remove blood clots from the peripheral venous vasculature, was introduced by Argon Medical Devices, a leading provider of medical device solutions for interventional radiology, vascular surgery, interventional cardiology, and oncology procedures. A single-use, large-bore aspiration tool called the CLEANER Vac Thrombectomy System was developed to quickly and effectively remove blood clots, also known as thrombus, from veins with restricted blood flow.

Favorable Healthcare Policies and Reimbursement Support

Supportive government policies and reimbursement frameworks create a positive clot management devices market outlook by making advanced clot management treatments more accessible. Many countries, including the United States, offer favorable insurance coverage for thrombectomy procedures, encouraging more hospitals and healthcare providers to adopt these technologies. Regulatory approvals from agencies like the FDA and CE mark certification for new clot management devices further drive market expansion. For instance, in March 2023, Penumbra received approval from the Food and Drug Administration to introduce Lightning Bolt 7, a revolutionary arterial thrombectomy system. The technology employs pressure sensors and an algorithm to determine whether the device is pulling in blood or a clot and modulates aspiration to remove blood clots. Penumbra, situated in Alameda, California, anticipates a 23% to 25% increase in sales in 2023 due to the Lightning Bolt 7 product and the recent introduction of Lightning Flash, another vascular device. Additionally, increasing healthcare expenditures and investments in medical infrastructure create opportunities for manufacturers to introduce innovative clot management solutions, ensuring broader patient access to life-saving treatments.

Clot Management Devices Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global clot management devices market, along with forecasts at the global, regional, and country levels from 2026-2034. The market has been categorized based on product type, and end-user.

Analysis by Product Type:

• Neurovascular Embolectomy Devices
• Embolectomy Balloon Catheters
• Percutaneous Thrombectomy Devices
• Mechanical Thrombectomy
• Aspiration Thrombectomy
• Percutaneous Mechanical Thrombectomy (PMT)
• Catheter-Directed Thrombolysis Devices
• Inferior Vena Cava Filters
• Permanent
• Retrievable

Percutaneous thrombectomy devices stand as the largest product type in 2025, holding around 37.6% of the market due to their effectiveness in rapidly removing blood clots with minimal invasiveness. These devices are widely used in treating deep vein thrombosis, pulmonary embolism, and arterial thrombosis, reducing the risk of complications and improving patient outcomes. Advancements in technology have enhanced their precision and efficiency, making them a preferred choice among healthcare professionals. Additionally, the growing prevalence of cardiovascular diseases, an aging population, and increasing demand for faster recovery times further drive their adoption. Their ability to minimize hospital stays and healthcare costs also boosts market growth.

Analysis by End-User:

• Hospitals
• Diagnostic Centers and Specialty Clinics

Hospitals leads the market with around 80.9% of market share in 2025 due to their advanced infrastructure, skilled healthcare professionals, and ability to handle complex thrombectomy procedures. They offer a wide range of clot management treatments, including percutaneous thrombectomy, catheter-directed thrombolysis, and surgical thrombectomy, ensuring comprehensive patient care. The increasing prevalence of cardiovascular diseases and emergency cases requiring immediate clot removal further drive demand. Additionally, hospitals have better access to cutting-edge medical technologies and government funding, enhancing treatment efficiency. The rising number of hospital admissions for thrombotic disorders and the availability of reimbursement policies also contribute to their market dominance.

Regional Analysis:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

In 2025, North America accounted for the largest market share of over 55.3%. The clot management devices demand in North America is influenced by the high prevalence of cardiovascular diseases, stroke, deep vein thrombosis, and pulmonary embolism. The region's advanced healthcare infrastructure, strong presence of key medical device manufacturers, and increasing adoption of minimally invasive procedures contribute to market growth. Favorable reimbursement policies, high healthcare spending, and government support for advanced medical technologies further enhance accessibility. Additionally, rising awareness of early clot detection and treatment, coupled with a growing geriatric population prone to thrombotic disorders, fuels demand. Technological advancements and an increasing number of outpatient procedures also play a significant role.

Key Regional Takeaways:

United States Clot Management Devices Market Analysis

In 2025, the United States accounted for over 89.80% of the clot management devices market in North America. The United States clot management devices market is primarily driven by the rising incidence of cardiovascular diseases, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke, driven by an increasing geriatric population and growing obesity rates. According to the Population Reference Bureau, the number of individuals aged 65 and above in the United States will reach 82 million by 2050, accounting for 23% of the population of the country. Moreover, the prevalence of atrial fibrillation, a key risk factor for thromboembolic events, is also rising, propelling the need for advanced clot removal solutions. Technological advancements in thrombectomy and embolectomy devices, such as catheter-directed thrombolysis and aspiration thrombectomy, are also improving procedural efficiency and patient outcomes, fueling adoption in hospitals and ambulatory surgical centers. Additionally, the growing preference for minimally invasive procedures over conventional surgical interventions is further contributing to industry expansion, as these devices reduce complications, hospital stays, and recovery times. Favorable reimbursement policies and guidelines from organizations such as the American Heart Association (AHA) and the U.S. Food and Drug Administration (FDA) further support the adoption of innovative clot management technologies. Besides this, expanding clinical research on novel clot management approaches is expected to further propel industry advancements.

Asia Pacific Clot Management Devices Market Analysis

The Asia Pacific clot management devices market is growing due to rising cases of atrial fibrillation and hypertension, both significant risk factors for thromboembolic disorders. Moreover, the increasing prevalence of cardiovascular diseases and venous thromboembolism (VTE), driven by aging populations, rising urbanization, and lifestyle-related risk factors such as diabetes, is also propelling the market. According to industry reports, 52.9% of the total population of Asia lived in urban areas in 2024, equating to 2,545,230,547 individuals. Additionally, rising awareness about stroke prevention and early treatment, driven by national health programs, is also encouraging the adoption of advanced clot removal technologies. Furthermore, the expansion of private healthcare facilities and the increasing presence of multinational medical device companies in emerging markets are improving access to cutting-edge thrombectomy and embolectomy solutions. Growing disposable incomes and improved insurance coverage are also making high-cost clot management procedures more accessible, supporting overall market growth.

Europe Clot Management Devices Market Analysis

The Europe clot management devices market is experiencing growth, fueled by the increasing prevalence of thromboembolic disorders, driven by aging demographics and sedentary lifestyles. The growing burden of non-communicable diseases, including hypertension, diabetes, and cardiovascular disorders, further elevates the risk of thromboembolic events. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) account for more than 42.5% of all deaths each year in Europe, making them the leading cause of premature death in the region. The widespread implementation of national stroke prevention programs and guidelines by organizations such as the European Society of Cardiology (ESC) and the European Stroke Organisation (ESO) is driving the adoption of advanced thrombectomy and thrombolysis devices. Increasing healthcare investments across Europe, particularly in digital health integration and AI-powered clot detection technologies, is further improving diagnosis and treatment precision. Additionally, the rising number of stroke centers and specialized vascular care units across countries such as Germany, the UK, France, and Italy is also boosting demand for advanced clot management technologies. Increasing awareness campaigns and training programs for healthcare professionals on thromboembolic disease management are further driving adoption. The rise in surgical procedures, particularly orthopedic and cancer-related surgeries, is also leading to a higher incidence of post-operative blood clots, propelling the need for effective clot management solutions.

Latin America Clot Management Devices Market Analysis

The Latin America clot management devices market is expanding due to the increasing prevalence of hypertension and metabolic disorders, which elevate the risk of thromboembolic events. Growing healthcare expenditure and government initiatives aimed at improving stroke care are enhancing access to advanced thrombectomy and thrombolysis procedures. For instance, as per the International Trade Administration (ITA), 9.47% of the GDP of Brazil is spent on healthcare, making it the largest market for healthcare in Latin America. The expansion of private hospitals and specialized stroke centers, particularly in Brazil, Mexico, and Argentina, is further supporting market growth. According to the ITA, 62% of the hospitals in Brazil are private. Besides this, strengthening regulatory frameworks and faster approval processes are also facilitating the introduction of new clot removal technologies in the region.

Middle East and Africa Clot Management Devices Market Analysis

The Middle East and Africa clot management devices market is propelled by an increasing geriatric population and a higher incidence of risk factors such as hypertension and dyslipidemia, increasing the likelihood of thromboembolic events. Expanding health insurance coverage and government subsidies in countries such as Saudi Arabia and the UAE are improving access to advanced clot removal procedures. For instance, according to the International Trade Administration, the Saudi Arabian government intends to invest more than USD 65 billion under Vision 2030 to build the nation's healthcare system and restructure and privatize insurance and health care. Additionally, local manufacturing initiatives and partnerships with international medical device companies are improving product availability and affordability. Growing medical tourism in the region is further supporting the adoption of advanced clot management technologies.

Competitive Landscape:

The market for clot management devices is extremely competitive, and major competitors are concentrating on product improvements, strategic mergers, and technology breakthroughs to improve their market positions. Major companies like Medtronic, Boston Scientific, Terumo Corporation, and Abbott Laboratories dominate the industry with a broad product portfolio and global presence. Startups and mid-sized firms are also entering the market, introducing novel minimally invasive solutions. Collaborations with healthcare providers and research institutions drive innovation. Regulatory approvals, reimbursement policies, and clinical trial success significantly impact market dynamics. Companies compete based on product efficacy, pricing, and distribution networks, making innovation and strategic expansion crucial.

The report provides a comprehensive analysis of the competitive landscape in the clot management devices market with detailed profiles of all major companies, including:

• AngioDynamics Inc.
• Argon Medical Devices Inc.
• Boston Scientific Corporation
• DePuy Synthes Inc.
• Edwards Lifesciences Corporation
• iVascular S.L.U.
• Lemaitre Vascular Inc.
• Medtronic Inc.
• Straub Medical AG
• Stryker Corporation
• Teleflex Incorporated
• Vascular Solutions

Key Questions Answered in This Report

1. How big is the clot management devices market?

2. What is the future outlook of the clot management devices market?

3. What are the key factors driving the clot management devices market?

4. Which region accounts for the largest clot management devices market share?

5. Which are the leading companies in the global clot management devices market?\

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Clot Management Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Neurovascular Embolectomy Devices
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Embolectomy Balloon Catheters
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Percutaneous Thrombectomy Devices
  • 6.3.1 Market Trends
  • 6.3.2 Major Types
    • 6.3.2.1 Mechanical Thrombectomy
    • 6.3.2.2 Aspiration Thrombectomy
    • 6.3.2.3 Percutaneous Mechanical Thrombectomy (PMT)
  • 6.3.3 Market Forecast
• 6.4 Catheter-Directed Thrombolysis Devices
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Inferior Vena Cava Filters
  • 6.5.1 Market Trends
  • 6.5.2 Major Types
    • 6.5.2.1 Permanent
    • 6.5.2.2 Retrievable
  • 6.5.3 Market Forecast

7 Market Breakup by End-User

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Diagnostic Centers and Specialty Clinics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Indicators

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 AngioDynamics Inc.
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Argon Medical Devices Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 Boston Scientific Corporation
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 DePuy Synthes Inc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
  • 13.3.5 Edwards Lifesciences Corporation
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
  • 13.3.6 iVascular S.L.U.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Lemaitre Vascular Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Medtronic Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 Straub Medical AG
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
  • 13.3.10 Stryker Corporation
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Teleflex Incorporated
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis
  • 13.3.12 Vascular Solutions
    • 13.3.12.1 Company Overview
    • 13.3.12.2 Product Portfolio